Johnson & Johnson’s drug for treatment-resistant depression got off to a slow start when it launched in 2019, but strong sales growth has put it on a blockbuster trajectory this year. 

When loss-making biotech companies mix debt with sluggish sales, difficult options like restructuring and asset sales remain.

Increased R&D spending, program acquisitions and a soaring headcount – Regeneron has seen significant growth over the past 5 years. The company is focused on marrying its antibody technologies with its expanding cell and gene therapy pipeline. 

2seventy bio sold full rights to a hemophilia A program and in vivo gene editing technology to partner Novo Nordisk.